Sanofi to review its new eczema drug amlitelimab - Meet them in May

Corvus shares nearly triple on positive data for eczema pill

An immune drug developer raises $50M to finance its eczema drug testing

Nektar sees silver lining as autoimmune drug ‘narrowly’ misses in alopecia study - Meet them in May

J&J eyes $100B in sales amid gains for cancer, immune drugs - Meet them in May

Alumis soars as TYK2 drug hits mark in psoriasis trials - Meet them in May

Galapagos TYK2 drug hits goal in one trial, misses in another

Takeda says $4B TYK2 drug succeeds in large psoriasis studies

Pfizer-backed Priovant scores again with fast-rising brepocitinib in midstage study

Connect’s Dupixent challenger hits the mark in phase 3 eczema trial

Apogee strengthens case for longer-lasting eczema drug

Torqur AG

Torqur AG, a subsidiary of Swiss Rockets AG and a Basel-based clinical-stage biotech founded in 2021, develops next-generation PI3K/mTOR inhibitors targeting key oncogenic pathways. The company advances innovative therapies across oncology and dermatology. Its lead candidate, bimiralisib, has successfully completed Phase II in Actinic Keratosis, demonstrating strong efficacy and favorable tolerability, and highlighting a differentiated, mechanism-driven approach to treating precancerous skin disease

View all Partners

Why Partner

Torqur AG

Torqur AG

Venue

Map

Contact

Join Our Team

About Us

Explore Our Products

Stay Connected

Search

Organized By